← FDA DRUG APPROVALS

FDA ANDA · ANDA211204

ERYTHROMYCIN ETHYLSUCCINATE

erythromycin

Sponsor: AMNEAL PHARMS

APPLICATION
ANDA211204
TYPE
ANDA
ORIGINAL APPROVAL
2019-11-01
LATEST ACTION
2019-11-01
ROUTE
ORAL
DOSAGE FORM
GRANULE
MARKETING STATUS
Prescription

Products

ERYTHROMYCIN ETHYLSUCCINATEPrescription
ERYTHROMYCIN ETHYLSUCCINATE EQ 200MG BASE/5ML · GRANULE · ORAL
ERYTHROMYCIN ETHYLSUCCINATEPrescription
ERYTHROMYCIN ETHYLSUCCINATE EQ 400MG BASE/5ML · GRANULE · ORAL

Approval history

2019-11-01UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →